Skip to content
2000
Volume 6, Issue 8
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

In most of the epilepsies and epileptic syndromes, the decision to initiate antiepileptic drug (AED) therapy is often a far simpler one than the decision to stop it. The primary factor that drives a patient to want to discontinue therapy, and a doctor to endorse or recommend this, is a fear of long-term adverse events, a consideration that may be entirely justified as the side effects of vigabatrin and felbamate have proved. On the other hand, seizure recurrence with the attendant implications in employment, driving regulations and social stigmatization is a strong deterrent that discourages withdrawal of therapy. The absence of a clearer understanding of the natural history and prognosis of many individual epilepsy syndromes somewhat hampers the resolution of this dilemma. Hopefully, as our understanding of the epilepsies grows and the prediction of the chances of seizure relapse becomes a more precise science, stopping medication will become a less fraught exercise for both the patient and the doctor.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612003400317
2000-05-01
2025-04-19
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612003400317
Loading

  • Article Type:
    Review Article
Keyword(s): Epilepsy; Epilepsy syndromes; Seizure freedom; Seizure recurrence
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test